

**Table 3. Clinical outcomes at the latest follow-up\***

<b>Outcomes</b>	<b>Values</b>
Total number of patients	73
Follow-up (days), median (IQR)	19.0 (15.0–27.0)
<b>Clinical outcomes</b>	
Status at Day 7	
Alive in the hospital	6 (8.2%)
Alive in the ICU	61 (83.6%)
Death	6 (8.2%)
Status at the latest follow-up	
Alive discharged home	5 (6.8%)
Alive discharged to other facilities	5 (6.8%)
Alive in the hospital	13 (17.8%)
Alive in the ICU	33 (45.2%)
Death	17 (23.3%)
ICU mortality	14 (19.2%)
Duration of mechanical ventilation (days), median (IQR)	10.1 (8.0–14.3)
In survivors	10.6 (8.0–15.8)
ICU length of stay (days), median (IQR)	10.5 (8.0–15.0)
In survivors	11.0 (8.0–16.0)
Hospital length of stay (days), median (IQR)	16.0 (13.0–24.0)
In survivors	18.0 (14.8–25.2)
<b>Support at the latest follow-up</b>	
ECMO	5 (6.8%)
Tracheostomy	20 (27.4%)
Prone positioning	55/72 (76.4%)
Renal replacement therapy	16 (21.9%)
<b>Complications at the latest follow-up</b>	
Bacterial pneumonia	9 (12.3%)
Pneumothorax or pneumomediastinum	7 (9.6%)
Stroke	1 (1.4%)
Heart failure	7 (9.6%)
Cardiac arrhythmia	15 (20.5%)
Acute myocardial infarction	1 (1.4%)
Myocarditis/pericarditis	0 (0.0%)
Cardiac arrest	6 (8.2%)
Bacteraemia	27 (37.0%)
Other secondary infection	3 (4.1%)
Disseminated intravascular coagulation	2 (2.7%)
Transfusion of > 2 units of red blood cells	25 (34.2%)
Rhabdomyolysis	2 (2.7%)
Acute kidney injury	55 (75.3%)
Stage 1	23/55 (41.8%)
Stage 2	15/55 (27.3%)
Stage 3	17/55 (30.9%)
Minor gastrointestinal haemorrhage	1 (1.4%)
Gastrointestinal perforation	1 (1.4%)
Liver dysfunction	16 (21.9%)

Hyperglycaemia	14 (19.2%)
Acute thrombosis (other than pulmonary embolism)	1 (1.4%)
Limb ischaemia	2 (2.7%)
Pulmonary embolism	4 (5.5%)
Minor (non-life threatening) bleeding	7 (9.6%)
Fungal infection	12 (16.4%)

ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; IQR = interquartile range.  
\* Latest follow-up at 1 April 2020. Percentages may not total 100 because of rounding.